Nachum Kaplan

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo.

The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivo.

Journal: Nature communications

Published: December 19, 2023

Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.

Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.

Journal: Oncogene

Published: April 14, 2022

In-vitro activity of tigecycline against multidrug-resistant Gram negative bacteria: The experience of a university hospital.

In-vitro activity of tigecycline against multidrug-resistant Gram negative bacteria: The experience of a university hospital.

Journal: Journal of infection and public health

Published: February 28, 2020

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects.

Journal: Journal of chemotherapy (Florence, Italy)

Published: October 03, 2015

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.

Journal: Future microbiology

Published: September 12, 2015

Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.

Journal: Antimicrobial agents and chemotherapy

Published: December 22, 2014

Oncogenic RIT1 mutations in lung adenocarcinoma.

Oncogenic RIT1 mutations in lung adenocarcinoma.

Journal: Oncogene

Published: June 26, 2013

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: April 26, 2013

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.

Journal: Antimicrobial agents and chemotherapy

Published: March 06, 2013

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.

Journal: Journal of chemotherapy (Florence, Italy)

Published: February 26, 2013

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.

Journal: Journal of chemotherapy (Florence, Italy)

Published: February 26, 2013

Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Journal: Antimicrobial agents and chemotherapy

Published: September 06, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026